Treatment Of Hemophilia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Treatment Of Hemophilia stocks.

Treatment Of Hemophilia Stocks Recent News

Date Stock Title
Nov 1 ALNY Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
Nov 1 BIIB Biogen partner Eisai completes FDA submissions for injectable Alzheimer’s therapy
Nov 1 ALNY Alnylam Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Nov 1 BIIB Biogen Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Nov 1 ALNY Alnylam Pharmaceuticals Inc (ALNY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Nov 1 ALNY Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
Nov 1 ALNY Q3 2024 Alnylam Pharmaceuticals Inc Earnings Call
Oct 31 BIIB Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter
Oct 31 ALNY Alnylam Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
Oct 31 ALNY Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2024 Earnings Call Transcript
Oct 31 BIIB Biogen down as Morgan Stanley cuts rating on sluggish Alzheimer’s drug launch
Oct 31 BIIB Biogen slips as Morgan Stanley downgrades on Leqembi launch
Oct 31 ALNY Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say
Oct 31 ALNY Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates
Oct 31 ALNY Alnylam: Q3 Earnings Snapshot
Oct 31 ALNY Alnylam Pharmaceuticals Non-GAAP EPS of -$0.50 misses by $0.11, revenue of $500.92M misses by $26.1M
Oct 31 ALNY Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity
Oct 31 BIIB Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic ...
Oct 30 BIIB Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
Oct 30 ALNY Alnylam Pharmaceuticals Q3 2024 Earnings Preview
Treatment Of Hemophilia

Treatment of hemophilia typically involves the use of replacement therapy, which involves infusions of clotting factor concentrates. These concentrates are made from donated human plasma and are designed to replace the missing clotting factor in the blood. Other treatments may include physical therapy, medications to reduce pain and swelling, and surgery to repair damaged joints.

Browse All Tags